Lactobacillus Acidophilus

Summary

Lactobacillus Acidophilus (CHEMBL2109070) is a phase-3 clinical-stage unknown; indicated across 26 conditions including crohn disease and irritable bowel syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 26 conditions
• Clinical trials: 23

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109070
Name	Lactobacillus Acidophilus
Type	Unknown
Max phase	3

Also known as: Acidophilus, Bacillus acidophilus whole, Bacterium acidophilum whole, Gynatren, Lacteol, Lactobacillus acidophilus, Lactobacillus acidophilus whole, Lactobacterium acidophilum whole, Thermobacterium intestinale whole, LACTOBACILLUS ACIDOPHILUS

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

24 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Crohn disease	3	MONDO:0005011	EFO:0000384
irritable bowel syndrome	3	MONDO:0005052	EFO:0000555
rectal cancer	3	MONDO:0006519	EFO:1000657
seasonal allergic rhinitis	3	MONDO:0005324	EFO:0003956
stomatitis	3	MONDO:0004842	EFO:1001904
brain disorder	3	MONDO:0005560	HP:0001298
Parkinson disease	3	MONDO:0005180	MONDO:0005180
diarrheal disease	2	MONDO:0001673	HP:0002014
osteoporosis	2	MONDO:0005298	EFO:0003882
constipation disorder	2	MONDO:0002203	HP:0002019
mastitis	2	MONDO:0006849	EFO:1001034
epilepsy	2	MONDO:0005027	EFO:0000474
ulcerative colitis	2	MONDO:0005101	EFO:0000729
Hirschsprung disease	2	MONDO:0018309	MONDO:0018309
infectious disease	2	MONDO:0005550	EFO:0005741
intestinal disorder	2	MONDO:0005020	HP:0002242
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915
sinusitis	2	MONDO:0005961	EFO:0007486
breast neoplasm	2	MONDO:0021100	MONDO:0007254
Klebsiella infectious disease	1	MONDO:0030603	EFO:1001353
fatty liver disease	1	MONDO:0004790	HP:0001397
metabolic dysfunction-associated steatotic liver disease	1	MONDO:0013209	EFO:0003095
psoriasis	1	MONDO:0005083	EFO:1001494
asthma	1	MONDO:0004979	MONDO:0004979

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
Not specified	10
PHASE4	4
PHASE3	4
PHASE2	3
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04527055	PHASE4	ENROLLING_BY_INVITATION	The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
NCT01558388	PHASE4	UNKNOWN	Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy
NCT04603456	PHASE4	COMPLETED	miRNA-155 Assay Before and After Immunotherapy and Probiotics
NCT07144475	PHASE4	COMPLETED	Comparison of Probiotic Effects on the Outcomes of Patients After Colorectal Cancer Surgery
NCT05576818	PHASE3	RECRUITING	Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson’s Disease
NCT00328263	PHASE3	COMPLETED	Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
NCT00554736	PHASE3	WITHDRAWN	Lactobacillus Acidophilus L92 on Markers of Allergic Inflammation by Nasal Provocation With Grass Pollen
NCT01202630	PHASE3	SUSPENDED	BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection
NCT00746226	PHASE1/PHASE2	COMPLETED	Probiotics for Birch Pollen Allergy
NCT01048567	PHASE2	TERMINATED	Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
NCT02535962	PHASE2	WITHDRAWN	Probiotics and Corticosteroids for Treating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA)
NCT05433857	PHASE2	COMPLETED	Probiotics in Systemic Lupus Erythematosus
NCT04364750	EARLY_PHASE1	COMPLETED	Biomarkers of Diet-microbiota Interactions in Irritable Bowel Syndrome
NCT05656209	Not specified	NOT_YET_RECRUITING	LA Improves the Prognosis of Patients With ICVD After Surgery
NCT05845983	Not specified	NOT_YET_RECRUITING	LA Improves the Prognosis of Patients With ICVD
NCT06830824	Not specified	NOT_YET_RECRUITING	Supplementation of Inulin + L. Acidophilus in Elders with T2DM
NCT00768794	Not specified	COMPLETED	Acidophilus for the Treatment and Prevention of Oral Candidiasis in Patients Undergoing Radiation Therapy
NCT01102036	Not specified	COMPLETED	Effects of Cultura Yoghurt in Relation to Transit Time and Digestive Discomfort in Healthy Women and Men
NCT02001610	Not specified	COMPLETED	Acidophilus Pearls Fecal Recovery Study
NCT02642289	Not specified	COMPLETED	Probiotics: Clinical Intervention Trial in Patients With Fibromyalgia
NCT04531033	Not specified	COMPLETED	Does Daily Supplementation of Lactobacillus Acidophilus MPH734, for One Week, Affect Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo
NCT04988594	Not specified	COMPLETED	Effects of Yogurt With Probiotics in Adults With Type 2 Diabetes Mellitus
NCT06035835	Not specified	COMPLETED	Probiotics and Breastmilk Decrease Risk of Atopic Dermatitis in Premature Infants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).